JPMorgan Chase & Co. Purchases 622,370 Shares of CVRx, Inc. (NASDAQ:CVRX)

JPMorgan Chase & Co. grew its position in shares of CVRx, Inc. (NASDAQ:CVRX - Free Report) by 10,520.1% during the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 628,286 shares of the company's stock after buying an additional 622,370 shares during the quarter. JPMorgan Chase & Co. owned 2.59% of CVRx worth $7,960,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other institutional investors and hedge funds have also recently modified their holdings of the company. Emerald Advisers LLC grew its position in CVRx by 47.3% during the fourth quarter. Emerald Advisers LLC now owns 593,898 shares of the company's stock valued at $7,525,000 after buying an additional 190,844 shares during the period. Geode Capital Management LLC grew its position in shares of CVRx by 2.2% during the 3rd quarter. Geode Capital Management LLC now owns 295,124 shares of the company's stock valued at $2,600,000 after acquiring an additional 6,443 shares during the period. State Street Corp grew its position in shares of CVRx by 11.4% during the 3rd quarter. State Street Corp now owns 264,733 shares of the company's stock valued at $2,332,000 after acquiring an additional 27,071 shares during the period. Bank of New York Mellon Corp increased its stake in shares of CVRx by 4.5% in the 4th quarter. Bank of New York Mellon Corp now owns 30,377 shares of the company's stock worth $385,000 after purchasing an additional 1,296 shares in the last quarter. Finally, Barclays PLC raised its holdings in CVRx by 312.5% in the 3rd quarter. Barclays PLC now owns 19,067 shares of the company's stock worth $169,000 after purchasing an additional 14,445 shares during the period. 75.27% of the stock is currently owned by hedge funds and other institutional investors.

CVRx Price Performance

CVRX traded down $0.03 during trading on Tuesday, reaching $6.03. 294,600 shares of the company traded hands, compared to its average volume of 319,187. The company has a market cap of $157.00 million, a P/E ratio of -2.24 and a beta of 1.34. The company has a debt-to-equity ratio of 0.69, a quick ratio of 10.23 and a current ratio of 12.06. CVRx, Inc. has a 12-month low of $5.81 and a 12-month high of $18.55. The firm has a fifty day simple moving average of $11.01 and a 200 day simple moving average of $12.74.

CVRx (NASDAQ:CVRX - Get Free Report) last posted its earnings results on Tuesday, February 4th. The company reported ($0.43) earnings per share for the quarter, missing the consensus estimate of ($0.37) by ($0.06). CVRx had a negative net margin of 116.91% and a negative return on equity of 93.06%. On average, equities analysts forecast that CVRx, Inc. will post -1.91 EPS for the current year.

Analyst Ratings Changes

Several analysts have issued reports on CVRX shares. Lake Street Capital cut their price target on CVRx from $19.00 to $14.00 and set a "buy" rating for the company in a report on Tuesday, April 8th. Craig Hallum boosted their price objective on CVRx from $20.00 to $22.00 and gave the company a "buy" rating in a research note on Friday, January 17th. Canaccord Genuity Group decreased their target price on shares of CVRx from $23.00 to $18.00 and set a "buy" rating on the stock in a research note on Tuesday, April 8th. Piper Sandler upped their price target on shares of CVRx from $16.00 to $20.00 and gave the stock an "overweight" rating in a research report on Wednesday, February 5th. Finally, William Blair upgraded shares of CVRx from a "market perform" rating to an "outperform" rating in a research report on Tuesday, January 14th. One investment analyst has rated the stock with a hold rating and six have assigned a buy rating to the company's stock. According to data from MarketBeat.com, the stock has a consensus rating of "Moderate Buy" and a consensus price target of $16.83.

About CVRx

CVRx, Inc, a commercial-stage medical device company, focuses on developing, manufacturing, and commercializing neuromodulation solutions for patients with cardiovascular diseases. The company offers Barostim, a neuromodulation device indicated to improve symptoms for patients with heart failure with reduced ejection fraction or systolic heart failure.